Beta Bionics (NASDAQ:BBNX) Releases Earnings Results, Beats Estimates By $0.01 EPS

Beta Bionics (NASDAQ:BBNX) posted its earnings results on Tuesday. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.01, FiscalAI reports. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The firm had revenue of $35.51 million during the quarter.

Beta Bionics Price Performance

Shares of Beta Bionics stock traded up $0.88 on Tuesday, reaching $21.39. The company had a trading volume of 1,363,349 shares, compared to its average volume of 1,176,469. The firm has a market cap of $962.34 million, a price-to-earnings ratio of -12.96 and a beta of 3.39. The firm’s 50-day moving average price is $19.16 and its two-hundred day moving average price is $15.02. Beta Bionics has a 1 year low of $8.80 and a 1 year high of $32.71.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The recent increase may reflect a rebound after the sharp selloff and technical buying. However, none of the reports published in the past two days identifies a new fundamental development that would clearly support the move higher.
• Neutral Sentiment: Multiple law firms, including Bragar Eagel & Squire, Kaplan Fox, Berger Montague, Rosen, and others, reminded investors that November 3, 2026, is the deadline to seek lead-plaintiff status in a pending securities class action. The notices primarily seek investor participation and do not represent a new regulatory finding. Bragar Eagel & Squire deadline notice
• Negative Sentiment: The lawsuits allege that Beta Bionics and certain executives failed to disclose or misrepresented important information about the iLet’s safety, efficacy, commercial performance, a June 2025 FDA Form 483, and more than 18,000 allegedly unreported customer complaints. The complaints claim that subsequent disclosures, including an FDA Warning Letter, contributed to a cumulative decline of roughly $23.09 per share. These allegations have not been proven, but continued legal publicity adds reputational, financial, and regulatory uncertainty. BBNX investor alert

Insider Activity

In related news, insider Steven Russell sold 4,221 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $80,663.31. Following the completion of the sale, the insider directly owned 169,628 shares in the company, valued at $3,241,591.08. This trade represents a 2.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Stephen Feider sold 6,675 shares of Beta Bionics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the transaction, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at $3,045,713.58. The trade was a 4.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 98,472 shares of company stock worth $1,920,481. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BBNX. BlackRock Inc. bought a new stake in Beta Bionics in the second quarter worth about $52,340,000. Eversept Partners LP increased its stake in Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the period. Bank of America Corp DE bought a new stake in shares of Beta Bionics during the second quarter worth $8,566,000. Perceptive Advisors LLC lifted its position in shares of Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares during the last quarter. Finally, Bruce & Co. Inc. bought a new stake in shares of Beta Bionics during the first quarter worth $5,518,000.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BBNX shares. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Leerink Partners lifted their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, September 14th. The Goldman Sachs Group boosted their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. William Blair began coverage on shares of Beta Bionics in a report on Friday, August 21st. They issued a “market perform” rating on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Beta Bionics in a research report on Monday, October 12th. They set a “buy” rating and a $30.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and an average price target of $24.00.

About Beta Bionics

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.